- Home
- CNTB vs ANEB Comparison
CNTB vs ANEB Comparison
Compare CNTB & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- ANEB
- Stock Information
- Founded
- CNTB 2012
- ANEB 2020
- Country
- CNTB United States
- ANEB United States
- Employees
- CNTB N/A
- ANEB N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- ANEB Health Care
- Exchange
- CNTB Nasdaq
- ANEB Nasdaq
- Market Cap
- CNTB 93.9M
- ANEB 96.8M
- IPO Year
- CNTB 2021
- ANEB 2021
- Fundamental
- Price
- CNTB $2.80
- ANEB $2.45
- Analyst Decision
- CNTB Strong Buy
- ANEB Buy
- Analyst Count
- CNTB 3
- ANEB 2
- Target Price
- CNTB $8.33
- ANEB $8.00
- AVG Volume (30 Days)
- CNTB 591.8K
- ANEB 13.5K
- Earning Date
- CNTB 11-12-2025
- ANEB 11-13-2025
- Dividend Yield
- CNTB N/A
- ANEB N/A
- EPS Growth
- CNTB N/A
- ANEB N/A
- EPS
- CNTB N/A
- ANEB N/A
- Revenue
- CNTB $762,000.00
- ANEB N/A
- Revenue This Year
- CNTB N/A
- ANEB N/A
- Revenue Next Year
- CNTB $453,067.90
- ANEB N/A
- P/E Ratio
- CNTB N/A
- ANEB N/A
- Revenue Growth
- CNTB N/A
- ANEB N/A
- 52 Week Low
- CNTB $0.51
- ANEB $0.80
- 52 Week High
- CNTB $3.28
- ANEB $3.42
- Technical
- Relative Strength Index (RSI)
- CNTB 68.76
- ANEB 51.83
- Support Level
- CNTB $1.49
- ANEB $2.27
- Resistance Level
- CNTB $3.28
- ANEB $2.47
- Average True Range (ATR)
- CNTB 0.33
- ANEB 0.09
- MACD
- CNTB 0.12
- ANEB -0.00
- Stochastic Oscillator
- CNTB 73.01
- ANEB 82.76
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.